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Abstract
 
Mast cells perform a significant role in the host defense against parasitic and some bacterial in-
fections. Here we show that in the dog, degranulation of brain mast cells evokes hypothalamic-
pituitary-adrenal responses via histamine release. A large number of mast cells were found in a
circumscribed ventral region of the hypothalamus, including the pars tuberalis and median em-
inence. When these intracranial mast cells were passively sensitized with immunoglobulin E via
either the intracerebroventricular or intravenous route, there was a marked increase in the ad-
renal cortisol secretion elicited by a subsequent antigenic challenge (whether this was delivered
via the central or peripheral route). Comp.48/80, a mast cell secretagogue, also increased corti-
sol secretion when administered intracerebroventricularly. Pretreatment (intracerebroventricu-
larly) with anti-corticotropin–releasing factor antibodies or a histamine H
 
1
 
 blocker, but not an
H
 
2
 
 blocker, attenuated the evoked increases in cortisol. These data show that in the dog, de-
granulation of brain mast cells evokes hypothalamic-pituitary-adrenal responses via centrally re-
leased histamine and corticotrophin-releasing factor. On the basis of these data, we suggest that
intracranial mast cells may act as an allergen sensor, and that the activated adrenocortical re-
sponse may represent a life-saving host defense reaction to a type I allergy.
Key words: hypersensitivity • immunoglobulin E • histamine • corticotropin-releasing factor • 
adrenal cortisol secretion
 
Introduction
 
Although they represent a line of host defense against acute
bacterial peritonitis (1, 2), mast cells, key cells in trigger-
ing immediate hypersensitive reactions, have long been
thought to play a life-threatening role in IgE-dependent al-
lergic reactions (3, 4). Connective tissue-type mast cells are
abundant in the circumventricular organs in a variety of
mammalian brains (5–9). Mast cells interact functionally
with neurons in the peripheral or central nervous systems
(8–10), and degranulate in response to physical or psycho-
logical stress (6, 7, 11, 12). Interestingly, in the median em-
 
inence (ME),
 
*
 
 but not in the leptomeninges, numerous
mast cells are found close to corticotropin-releasing factor
(CRF)-positive nerve processes (12). Furthermore, anaphy-
lactic shock and administration of histamine, a chemical
mediator preformed in mast cells, both evoke a hypotha-
lamic-pituitary-adrenal (HPA) response (13–18). To us,
these findings suggested the speculative notion that brain
mast cells may act to increase adrenocortical secretion when
immediate hypersensitivity occurs. However, the physio-
logical role of brain parenchymal mast cells, especially those
located in the ME, is poorly understood. In dogs passively
sensitized with IgE, we studied whether, and how, degran-
ulation of the brain mast cells in response to an antigenic
challenge might lead to activation of the HPA axis.
 
Materials and Methods
 
IgE Preparations.
 
To obtain dog anti-OVA IgE antibodies, a
previously described method for immunization that induces pro-
duction of IgE (19) was employed, as follows. 50 
 
 
 
g of OVA dis-
solved in 1.0 ml saline with 12 mg Al
 
2
 
(OH)
 
3
 
 was intraperito-
neally administered to newborn mongrel dogs within 24 h after
their birth, and boosters were given at 1-mo intervals. The titer
of IgE antibodies against OVA was measured by the passive cuta-
neous anaphylaxis (PCA) method at least 2 d after a passive sensi-
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Abbreviations used in this paper:
 
 ACSF, artificial cerebrospinal fluid;
ACTH, adrenocorticotropic hormone; AH, adenohypophysis; BBB,
blood-brain barrier; BP, blood pressure; CRF, corticotropin-releasing
factor; EAML, external auditory meatus line; HPA, hypothalamic-pitu-
itary-adrenal; HR, heart rate; icv, intracerebroventricular; ME, median
eminence; PCA, passive cutaneous anaphylaxis; PT, pars tuberalis; V
 
III
 
,
cerebral third ventricle. 
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tization in immune naive dogs (19). The IgE (titer between 600
and 800 times) produced by three dogs was used in this study. To
determine whether the adrenal responses were induced by IgE
antibodies or IgG1 antibodies, denatured serum for immuniza-
tion was prepared by heating at 56
 
 
 
C for 2 h (20, 21).
 
Animals.
 
Adult male mongrel dogs weighing from 10.2 to
12.3 kg were used in the experiments designed to investigate the
IgE-dependent HPA response. The protocols conformed with
guidelines on the conduct of animal experiments issued by the
Animal Care and Use Committee of Nagasaki University. All an-
imal experiments were performed under sodium pentobarbital
anesthesia (25 mg/kg, intravenously). For passive sensitization via
the intracerebroventricular (icv) route, 2.0 ml immunized serum
was ultrafiltrated using a diaflow membrane filter (CF50; Ami-
con; substances below 50,000 mol wt are filtered out) for 2 h at
800 
 
g
 
. Once made up to 1.0 ml with artificial cerebrospinal fluid
(ACSF), the ultrafiltrated serum was infused through a 27-gauge
needle held within a cerebral guide cannula (22-gauge stainless
steel) stereotaxically implanted into the cerebral third ventricle
(V
 
III
 
). This infusion was given for 4 h at a rate of 4.2 
 
 
 
l/min
some 24 h before an antigenic challenge. For passive sensitization
via the intravenous (iv) route, 2.0 ml immunized serum was in-
fused into the saphenous vein over a 4-h period. To collect adre-
nal venous blood, a glass cannula was placed into the left lumbo-
adrenal vein through a retroperitoneal lumbar approach (22). The
antigenic challenge was delivered by infusing OVA dissolved in
ACSF at a rate of 16 
 
 
 
l/min for 5 min via the icv or iv routes.
Adrenal blood samples were collected in graduated tubes at 10
min before, and at 20, 30, and 60 min after an antigenic or phar-
macologic challenge. These samples were centrifuged immedi-
ately after collection. The cortisol in the adrenal venous plasma
was determined by the fluorometric method, the adrenal cortisol
secretion rate being calculated in 
 
 
 
g/kg body weight/min (13).
Blood pressure (BP) and heart rate (HR) were monitored from
the femoral artery before and after an antigenic challenge. Lyoph-
ilized anti-CRF antiserum (equivalent to 12.5 
 
 
 
l rabbit antiserum
against human CRF; Sigma-Aldrich) was dissolved in 500 
 
 
 
l
ACSF and infused into the V
 
III
 
 at a rate of 16 
 
 
 
l/min for 30 min
(ending 5 min before the onset of an antigenic or pharmacologic
challenge). Pyrilamine maleate (2.0 
 
 
 
g/kg; Sigma-Aldrich) or
metiamide (200 
 
 
 
g/kg; SKF-Japan) was dissolved in ACSF and
infused into the V
 
III
 
 at a rate of 16 
 
 
 
l/min for 30 min (ending 5
min before the onset of the above challenges).
 
Histology.
 
For the histological study, seven dogs of either sex
weighing between 4.5 and 12.3 kg that had received no experi-
mental treatment were given an overdose of pentobarbital so-
dium. The brain was perfused transcardially with saline contain-
ing 0.1 M phosphate buffer, pH 7.4 (immediately after the heart
stopped beating) followed by perfusion with 4% paraformalde-
hyde in 0.1 M phosphate buffer. After removing and trimming
the brain, serial coronal sections were cut on a microslicer (DTK-
1000; Dosaka EM) without freezing. Each serial section (100 
 
 
 
m
in thickness) was soaked in 0.1% aqueous toluidine blue (dis-
solved in phosphate buffer, pH 7.4). The following brain region
(shaded in Fig. 1 A, inset) was surveyed: longitudinal axis, from
14 mm rostral (posterior margin of the mammillary body) to 27
mm rostral (anterior margin of the optic chiasma) to the external
auditory meatus line (EAML; 
 
R
 
0
 
 in Fig. 1 A); vertical axis, from 2
mm above (basal part of the hypophysis) to 23 mm above (top
margin of the anterior commissure) the EAML; transverse axis,
from the midline to 3 mm either side. Each serial coronal section
was divided into several areas with the aid of a graduated eye-
piece fitted to a light microscope. In each of these areas, every
mast cell stained metachromatically was counted (panfocusing the
 
mast cells). Counting operations were performed in order from
the most rostral serial coronal section to the most caudal, and
then repeated in the reverse order. The numbers given for the
mast cells in each coronal section were obtained by taking the av-
erage of these two values.
 
Statistics.
 
Statistics were performed using a repeated one-way
or two-way analysis of variance (ANOVA) with a post hoc test
(Fisher’s Protected Least Significant Difference [PLSD]) for mul-
tiple comparisons.
 
Results
 
Numerous Mast Cells Are Found in a Lower Region of the
Hypothalamus.
 
In coronal serial sections of the dog brain,
large numbers of mast cells were found in the region be-
tween 18 and 20 mm (R
 
20
 
) rostral to the EAML (Fig. 1 A
and inset). They were largely found in the bottom of the
V
 
III
 
 (Fig. 1 B) and in a zone within 2 mm of the midline
on either side containing the ME (Fig. 1 C), the pars tu-
beralis (PT; Fig. 1 D), and the infundibular stalk. Most of
the mast cells located in the ME were found in close asso-
ciation with capillaries (solid arrow in Fig. 1, C and E, and
white arrow in Fig. 1 D). Large numbers of mast cells
were arranged side by side in the border region of the ven-
tral ME where neuronal tissues contact the basal part of
the adenohypophysis (AH) via the epithelium extending
from the PT (white arrowhead in Fig. 1 C). Mast cells
were also seen around the circumference of arteries or
veins running through the parenchyma of the brain areas
surveyed; however, the number of such mast cells did not
exceed five in a given serial coronal section. Although nu-
merous mast cells were seen within the anterior or poste-
rior pituitary gland or in the leptomeninges around the
areas surveyed, these were not included in the representa-
tion of the sagittal distribution of cell numbers shown in
Fig. 1 A.
 
An Antigen Challenge Evokes HPA Response via Histamine
in Sensitized Animals.
 
The protocols of the various exper-
iments carried out to study IgE-dependent adrenocortical
activation are summarized in Table I. The timing of the
peak secretion of adrenal cortisol in response to an anti-
genic challenge depended on whether the icv or iv route
was used to deliver the challenge. An antigen challenge
(1.6 
 
 
 
g/kg OVA) delivered via the icv route markedly in-
creased the adrenal cortisol secretion rate in dogs passively
sensitized with IgE via the icv route (Sicv/Cicv experi-
ment, Fig. 2 A). Plasma immunoreactive adrenocorticotro-
pic hormone (ACTH) was significantly increased at 20
min (data not shown) and the maximal cortisol secretion
rate (5 times the basal rate) was detected at 60 min after the
antigen challenge. These responses occurred without any
significant changes in arterial BP or HR (data not shown).
Pretreatment with anti-CRF antiserum (icv) significantly
attenuated the evoked increase in cortisol (Fig. 2 A). Fur-
thermore, pretreatment with pyrilamine maleate (2.0 
 
 
 
g/
kg), an H
 
1
 
-histaminergic antagonist, also suppressed the in-
crease completely when administered intracerebroventric-
ularly (Fig. 2 A), but not when the same dose was given
via the iv route (data not shown). By contrast, even a large 
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Figure 1. Mast cells in the dog brain. (A) Sagittal distribution of mast cells in the ventral hypothalamic region in serial coronal sections from 17 to 23
mm rostral to EAML (R0) in seven dogs. Inset: drawing of midline sagittal section of the brain. Shaded area was surveyed for mast cells. (B) Representa-
tive photomicrograph of a coronal section at 19.5 mm rostral to EAML in dog no. 0120. The section includes the bottom of the third ventricle (III), the
PT, the ME, and the AH, and it was stained with toluidine blue. Areas indicated by rectangles are depicted at high magnification in other photomicro-
graphs, as described below. (C) Photomicrograph of rectangular area C (see B). (D) Photomicrograph of rectangular area D (see B). (E) Photomicrograph
of area E (see C). Vertical bars, 100  m. (F) Photomicrograph of rectangular area F (see E). Arrows show numerous metachromatic red-purple granules
stained with toluidine blue in each mast cell. Original magnification:  1,000. 
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dose of metiamide (
 
 
 
200 
 
 
 
g/kg, icv), an H
 
2
 
-histaminer-
gic antagonist, did not significantly alter the increase (Fig.
2 A).
 
An Antigen Challenge Delivered Peripherally Can Reach In-
tracranial Mast Cells Sensitized via the Central Route.
 
In the
Sicv/Civ experiment, too, an antigen challenge (iv) in-
creased adrenal cortisol secretion, the secretion this time
peaking at 20 min after the challenge (Fig. 2 B). A signifi-
cant increase in cortisol was observed after a 4.8 
 
 
 
g/kg an-
tigen challenge (three times larger than that seen after an
icv antigen challenge), but not after a 1.6 
 
 
 
g/kg antigen
challenge (same dose as that used for the icv challenge). BP
and HR did not change significantly after the 4.8 
 
 
 
g/kg
OVA challenge (data not shown). Pretreatment (icv) with
an H
 
1
 
 blocker, but not with anti-CRF antiserum, signifi-
cantly suppressed the increase in cortisol (Fig. 2 B).
 
IgE Given Peripherally Can Sensitize Mast Cells Located in
the Intracranial Region.
 
In dogs sensitized with IgE via the
iv route, a marked increase in cortisol secretion rate (to 4.4
times the basal level) was evoked when a 1.6 
 
 
 
g/kg OVA
challenge was delivered via the icv route (Siv/Cicv experi-
ment, Fig. 3 A), but not when it was delivered via the iv
route (Siv/Civ experiment; Fig. 3 B). Pretreatment (icv)
with either an H
 
1
 
 antagonist or anti-CRF antiserum re-
duced the increase in cortisol by 61 and 51%, respectively,
of the peak response seen in dogs not given either of these
pretreatments (Fig. 3 A). In the Siv/Civ experiment, an an-
tigenic challenge significantly increased the cortisol secre-
tion rate when 8.0 
 
 
 
g/kg OVA (five times larger than the
dose used in the Sicv/Cicv experiment) was given, but not
when the dose used was 1.6 or 4.8 
 
 
 
g/kg OVA (Fig. 3 B).
Neither IgE denatured by heating nor immune naive sera
ever induced significant changes in adrenal cortisol secre-
tion, BP, or HR, nor did they induce a PCA reaction.
 
Pharmacologic Challenge also Activates HPA Response via
Histamine and CRF Release.
 
To confirm whether degran-
ulation of brain mast cells does or does not activate adreno-
cortical secretion, Comp.48/80, a specific mast cell secreta-
gogue, was employed. An icv administration of Comp.48/
80 significantly increased the cortisol secretion rate at 30
min after the pharmacologic challenge (Fig. 4) with a con-
comitant increase in plasma immunoreactive ACTH (data
not shown). Neither the plasma histamine level nor BP or
HR changed significantly as a result of the pharmacologic
challenge (data not shown). The Comp.48/80-evoked in-
crease in cortisol was completely suppressed by pretreat-
ment (icv) with anti-CRF antiserum or an H
 
1
 
-histaminer-
gic blocker, but not by pretreatment with an H
 
2
 
 blocker.
These findings were similar to those obtained in experi-
ments in which activation of the HPA response was evoked
by IgE-dependent degranulation (Figs. 2 A and 3 A).
 
Discussion
 
The reaginic hypersensitivity of the sera used in these
experiments to OVA antigen, which induced the observed
adrenal responses and PCA reactions, was completely abol-
ished by heating the sera at 56
 
 
 
C for 2 h. The reaginic ac-
tivity was detectable by the presence of homogenous PCA
reactions within 3 d after passive sensitization of the skin.
This shows that the central role in the activation of the
HPA axis is played by the IgE antibodies, rather than IgG1
Figure 2. Effect of an antigenic challenge (C) delivered via the icv (A)
or iv (B) route on adrenal cortisol secretion rate in dogs sensitized (S)
with IgE via the icv route. (A) In the Sicv/Cicv experiment, cortisol se-
cretion increased dramatically after a 1.6  g/kg OVA challenge in dogs
sensitized with IgE (but not in those given denatured IgE). The increase
was attenuated by pretreatment with anti-CRF antiserum or an H1
blocker, but not by pretreatment with an H2 blocker. (B) In the Sicv/
Civ experiment, cortisol secretion increased markedly in response to a
4.8  g/kg OVA challenge via the iv route, but this did not occur with a
1.6  g/kg OVA challenge via the same route. An H1 blocker signifi-
cantly attenuated the increase, but anti-CRF antiserum did not. Num-
bers in parenthesis indicate number of animals. All data are means   SE.
**P   0.01 versus animals sensitized with heat-inactivated IgE. †P  
0.05, ††P   0.01 versus animals without pretreatment.
 
Table I.
 
Summary of Experimental Protocols
 
Sensitization (S) with IgE
icv iv
Challenge (C)
with antigen
icv Sicv/Cicv (Fig. 2 A) Siv/Cicv (Fig. 3 A)
iv Sicv/Civ (Fig. 2 B) Siv/Civ (Fig. 3 B) 
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antibodies, present in the actively immunized sera em-
ployed in our experiments (8, 20, 21).
In our first set of experiments, in dogs sensitized with
IgE via the icv route, an antigenic challenge delivered via
either the icv or iv route evoked an increased HPA re-
sponse (in the Sicv/Cicv and Sicv/Civ experiments; Fig.
2). The adrenal cortisol secretion rate increased markedly in
response to a 1.6 
 
 
 
g/kg antigen challenge in the Sicv/Cicv
experiment. In the Sicv/Civ experiment, a 4.8 
 
 
 
g/kg anti-
genic challenge also evoked an HPA response, but a 1.6
 
 
 
g/kg antigen challenge did not. These evoked adrenal re-
sponses were (a) significantly reduced by pretreatment with
an H
 
1
 
 antagonist via the icv route, but not by such pretreat-
ment via the iv route, and (b) unchanged after pretreatment
with an H
 
2
 
 antagonist. In addition, a significant attenuation
of the HPA response evoked by an antigenic challenge
given via the icv route was observed when animals were
pretreated with an anti-CRF antiserum via the icv route. It
is well documented that an administration of histamine via
either the iv or icv route produces an HPA response (13–
18), and that the HPA activation induced by histamine
seems to be caused indirectly via activation of hypothalamic
neurons or release of neurotransmitters, including CRF,
arginin-vasopressin, and oxytocin (18, 23). Furthermore,
there is evidence that the histamine-induced ACTH secre-
tion is mediated by H
 
1
 
-histaminergic receptors (17, 18, 23–
26), although the sites of action are not well defined (16,
17). Following on from these studies, our data showed that
an antigenic challenge triggers degranulation of sensitized
brain mast cells, followed by liberation of histamine in an
intracranial region, and that the liberated histamine subse-
quently evokes a release of CRF (a neuropeptide that acti-
vates ACTH secretion from the pituitary gland) via H
 
1
 
 re-
ceptors located within the brain. Furthermore, our data
suggest that intracranial mast cells sensitized with IgE via
the icv route degranulate and liberate histamine even when
the antigen challenge is delivered via the iv route. In the
Sicv/Civ experiment, however, pretreatment with anti-
CRF had no significant effect on the evoked adrenal re-
sponse. This ineffectiveness of pretreatment with anti-CRF
antibodies against the increase in cortisol evoked by an iv
antigenic challenge may suggest that the mast cells that lib-
erate histamine in response to such a challenge are located
in intracranial regions other than the ME, probably in the
AH and/or PT. Another possibility is that hypothalamic
neurotransmitters or hormones, such as catecholamines, va-
sopressin, or oxytocin, may contribute to the activation of
the pituitary-adrenal response (17, 18, 23).
In the second set of experiments, involving dogs sensi-
tized with IgE via the iv route, antigenic challenge via ei-
ther the icv or iv route evoked significant increases in adre-
nal cortisol secretion (experiments Siv/Cicv and Siv/Civ;
Fig. 3). In the Siv/Cicv experiment, our results suggest that
a 1.6 
 
 
 
g/kg antigen challenge again evoked an adrenal re-
Figure 4. Effect of Comp.48/80 on adrenal cortisol secretion rate in
dogs. Comp.48/80 (Sigma-Aldrich) was given into VIII at a rate of 7.5
 g/kg/min for 5 min with or without antagonists. In response to
Comp.48/80, cortisol secretion increased to four times the basal level.
Pretreatment with anti-CRF antiserum or an H1 blocker significantly at-
tenuated the increase (but an H2 blocker did not). Numbers in parenthesis
indicate number of animals. All data are means   SE. **P   0.01 versus
vehicle control. ††P   0.01 versus animals without pretreatment.
Figure 3. Effect of an antigen challenge (C) delivered via the icv (A) or
iv (B) route on adrenal cortisol secretion rate in dogs sensitized (S) with
IgE via the iv route. (A) In the Siv/Cicv experiment, a 1.6  g/kg OVA
challenge markedly increased cortisol secretion in dogs sensitized with
IgE (but not in those given denatured IgE). The increase was attenuated
by pretreatment with anti-CRF antiserum or an H1 blocker. (B) In the
Siv/Civ experiment, an 8.0  g/kg OVA challenge increased cortisol se-
cretion significantly, but a 1.6 or 4.8  g/kg OVA challenge did not. The
increase after the 8.0  g/kg OVA challenge was markedly attenuated by
pretreatment with 200  g/kg of an H1 blocker (but not by 2  g/kg).
Numbers in parenthesis indicate number of animals. All data are means  
SE. **P   0.01 versus animals sensitized with heat-inactivated IgE. †P  
0.05, ††P   0.01 versus animals without pretreatment. 
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sponse via liberated histamine and subsequent release of
CRF. To evoke an adrenal response, the dose used for an-
tigenic challenge needed a larger dose (8.0  g/kg antigen)
in the Siv/Civ experiment than that needed in the Sicv/
Cicv (1.6  g/kg) or Sicv/Civ (4.8  g/kg) experiments.
These data indicate that intracranial mast cells can be sensi-
tized passively with IgE not only via the central route, but
also via the peripheral route. The above results also suggest
that mast cells located outside the blood-brain barrier
(BBB) in the intracranial region can be sensitized with IgE,
and show that an icv antigenic challenge can also trigger
degranulation of mast cells sensitized via the peripheral
route. This degranulation, too, may activate the HPA axis
via histamine and CRF released within the brain.
It has been well documented that there is a high density
of mast cells in the ME (12, 27–29) in various mammals. In
our study, numerous mast cells were identified morpholog-
ically in the ventral part of the hypothalamus (PT and ME)
in close association with the capillaries of the so-called pri-
mary plexus of the hypophyseal portal system. Previously,
the distribution and densities of H1 receptors in the brain
have been investigated using [3H]mepyramine in rats (30,
31) or [131I]iodobolpyramine in guinea pigs (32). These
studies showed that H1 receptors are widely distributed
within the brain. However, in the part of the hypothalamus
containing the ME, there are differences in the pharmacol-
ogy, density, and distribution of H1 receptors among the
rat, mouse, guinea pig, rabbit, and human brains (31–34).
At present, it is unclear whether H1 receptors are present in
the dog ME, and if they are, how many H1 receptors are
concentrated there. In our previous study, however, the
bulk of the histamine-induced increase in adrenal cortisol
secretion was abolished by lesions in the anterior or poste-
rior ME (13). Therefore, it seems likely that at least some
of the mast cells that degranulate in response to an anti-
genic or pharmacologic challenge are located in the ME
and PT, and that histamine liberated from these mast cells
may act on CRF-containing neuronal terminals in the ME
in a paracrine fashion (17).
Furthermore, the ME, which lacks the BBB, is a major
integrative link between neuronal terminals projecting
from the hypothalamic nuclei and the AH. This integration
is mediated not just by neurotransmitters and neuropep-
tides, but also by immune-mediated inflammatory sub-
stances (35). Thus, to judge from our data, the hypotha-
lamic mast cells would seem to be located in an ideal
position to detect and respond to exogenous agents as well
as to endogenous stimuli (2). However, we have no data to
help us decide whether exogenous antigens can gain access
to intracranial mast cells from the external world after
crossing the barriers in the respiratory or gastrointestinal
tracts. A degranulation of mast cells leads to an increased
permeability of blood vessels, so small and local, but re-
peated, activation of mast cells located in the airways or
peritoneal cavity might permit penetration of the antigen
into the circulatory system. However, this issue remains to
be resolved. A further point of interest is that CRF secreted
from sympathetic nerve terminals during stress can appar-
ently induce degranulation of mast cells located in the thal-
amus, leptomeninges, or peritoneal tissue (11, 12, 36).
Moreover, brain mast cells can be activated by direct stim-
ulation of sensory nerves (37) or by neuropeptides, such as
substance P (7, 37). Thus, on the basis of these data, brain
mast cells, some of which are located in the ME, may
cross-talk with CRF-containing neurons.
Mast cells have long been regarded as an appendix of the
human immune system, at least in the developed world,
because of their involvement in tissue-damaging processes
as well as in allergic and anaphylactic reactions. Indeed,
IgE-dependent immediate hypersensitivity reactions are
frequently associated with dysfunctions of the cardiovascu-
lar or respiratory systems, which can have life-threatening
consequences for allergic individuals (3, 4). However, both
pharmacologic glucocorticoids and physiologic adrenal
corticosteroids can ameliorate the severity of these dysfunc-
tions and suppress the subsequent immune-mediated in-
flammation (6, 35, 38–41). Thus, an activation of cortisol
secretion after degranulation of intracranial mast cells could
conceivably evoke a life-saving host defense response
against severe systemic anaphylaxis or respiratory disorders
when a type I allergic reaction is triggered by peripheral
mast cells. It may, indeed, provide a negative feedback
mechanism acting to modulate subsequently evoked pe-
ripheral inflammatory responses.
A very recent study indicated that mast cells may play a
major role in many immune-mediated diseases of the cen-
tral nervous system, such as experimental allergic encepha-
lomyelitis (42), as well as in alterations in the BBB (6). In
future, the experimental system employed in this study
(sensitization with IgE followed by antigenic challenge)
might be a useful experimental model for studying the in-
duction and/or progress of intracranial mast cell–related
neuroinflammatory conditions in vivo or for investigat-
ing mast cell–dependent alterations in the properties of
the BBB.
This study suggests that we need to enlarge our concept
of the role of intracranial mast cells; in fact, we need to add
a protective role in type I allergy to their previously re-
ported protective role during bacterial infections (1, 2). In-
tracranial mast cells located in the ME can be sensitized
with IgE, as can mast cells situated in the periphery. Intra-
cranial mast cells activated by a complex containing IgE
bound to Fc R1 and then antigen challenged are able to
evoke an HPA response, suggesting a link between intra-
cranial mast cells and neuroendocrine networks. Conse-
quently, the mast cells located in the ME and PT could be
seen as an immune gate to the HPA axis: upon receiving
antigenic information, intracranial mast cells would in ef-
fect communicate with neural and endocrine networks as
well as with other brain immune cells, such as microglia
and astrocytes (6, 7, 43, 44).
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